PROCEDURAL STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION

For procedures finalised after 1 April 2004 please refer to module 8B.

- On 2 April 1998, the European Commission approved a variation (Type I following type II) for the serum-free production of Epoetin beta.
- On 2 April 1998, the European Commission approved an Annex II application (Extension of the Marketing Authorisation) for 7 additional strengths/pharmaceutical forms (solution for injection). The relevant amendments have been incorporated in the relevant sections of the Commission Decision and of this EPAR.
- On 1 October 1998, the European Commission approved a type I variation submitted by the company relating to the change of name of the solution for injection presentations to "NeoRecormon <strength> IU solution for injection in pre-filled syringe". The relevant amendments have been incorporated in the relevant sections of the Commission Decision and of this EPAR.
- On 11 November 1998, the European Commission approved a type II variation for the extension of the shelf life to 3 years at 2 – 8 °C for NeoRecormon (powder and solvent for solution for injection) for the following strengths: 500 IU, 1000 IU, 2000 IU, 5000 IU and 10000 IU single dose and 50000 IU and 10000 IU multidose. The relevant amendments have been incorporated in the relevant sections of the Commission Decision and of this EPAR.
- On 11 November 1998, the European Commission approved a type II variation to change the needle size for NeoRecormon in pre-filled syringe and to update the SPC, PL and labels for all presentations. The relevant amendments have been incorporated in the relevant sections of the Commission Decision and of this EPAR.
- On 2 July 1998, the European Commission notified the EMEA, the Marketing Authorisation Holder and the members of the Standing Committee of a type I variation (change in bulk buffer) which does not require any amendment to the Commission Decision.
- On 7 May 1999 (date of notification: 12 March 1999), the European Commission approved a transfer of Marketing Authorisation from Boehringer Mannheim GmbH (Germany) to Roche Registration Ltd. (United Kingdom). The relevant amendments have been incorporated in the relevant sections of the Commission Decision and of this EPAR.
- On 1 July 1999, the European Commission approved a type I variation: changes following modification of the manufacturing authorisation (transfer of Marketing Authorisation). The relevant amendments have been incorporated in the relevant sections of the Commission Decision and of this EPAR.
- On 16 July 1999, the European Commission approved a type II variation: additional manufacturing site for the NeoRecormon pre-filled syringes 500 IU-20000 IU (Roche Diagnostics GmbH, Mannheim). The relevant amendments have been incorporated in the relevant sections of this EPAR.
- On 10 February 2000, the European Commission approved a type II variation: changes to SPC, labelling and package leaflet with regards to new template, amendments to sections 4.8 as a result of second PSUR and update of the addresses of local representatives in package leaflet. The relevant amendments have been incorporated in the relevant sections of the Commission Decision and of this EPAR.
- On 10 February 2000, the European Commission approved three Annex II application (Extension of the Marketing Authorisation) for 2 additional strengths of the solution for injection in pre-filled syringes and 1 additional strength of the powder and solvent for solution for injection in cartridge. The relevant amendments have been incorporated in the relevant sections of the Commission Decision and of this EPAR.

- On 20 March 2001, the European Commission approved a type II variation: additional indication. The relevant amendments have been incorporated in the relevant sections of the Commission Decision and of this EPAR.

Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below:

Scope	Application number	Type of modification[1]	Notification/ Opinion issued on[2]	Commission Decision Issued/amended on
Change to summary of product characteristics (section 4.2) and package leaflet to update the posology section in order to include a new, once weekly, frequency of administration.	II/15	II	31.05.01	17.09.01
Change in the batch size of finished product	I/16	I	14.05.01	
Change in test methods for the active substance	II/17	II	27.06.01	04.07.01
Change in test procedures of the medicinal product	I/II/18	I/II	27.06.01	06.07.01
Change in specifications for the active substance	II/19	II	15.11.01	19.11.01
Minor change in labelling and package leaflet not connected with the SPC (Art. 61(3) Notification)	N/20	N		29.09.01
Minor change in manufacturing of the medicinal product	I/21	I	21.02.02	01.03.02
Renewal	R/22	R	28.05.02	22.08.02
Change to summary of product characteristics (section 4.2) and package leaflet to update the posology section in order to include a new, once weekly, frequency of administration.	II/23	II	21.08.02	03.12.02
Additional secondary packing site	I/24	I	25.10.02	05.11.02
Update of Summary of Product Characteristics and Package Leaflet	II/26	II	18.12.02	17.03.03
Additional secondary packing site	I/27	I	25.10.02	05.11.02
Additional secondary packing site	I/28	I	08.11.02	08.11.02
Change in the batch size of finished product	I/29	I	23.01.03	27.01.03
Change(s) to the manufacturing process for the active substance	II/30	II	25.04.03	30.04.03
Addition of new strength	X/31	X	25.09.03	23.02.04

[1] In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: **I** refers to a minor variation (Type I variation); **II** refers to a major variation (Type II variation); **I/II** refers to a minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; **X** refers to an Annex II application.
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 November 1996.
N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992.

[2] For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date. The Commission Decision will be amended accordingly.